Houda Hachad, VP of Clinical Operations at Aranscia, AccessDx Laboratory’s parent company, commented on her recent co-authored paper released in The Journal of Molecular Diagnostics, “I am honored that I had the opportunity to serve on this amazing panel! We all gathered as representatives of our diverse international PGx community – from consortia leaders, molecular testing experts, and PGx implementers to streamline DPYD testing for all populations. Our joint consensus recommendation, including an expanded list of variants reported in diverse populations across the globe, is available to all – Let’s put it to use!
It is time to follow the steps of great implementers of preemptive DPYD testing, such as Atrium Health (read here: https://lnkd.in/gGu7U6dY), and others, and prevent unnecessary harm and hospitalizations.”
To read the full paper in JMD Journal, click here: https://www.jmdjournal.org/article/S1525-1578(24)00154-5/fulltext
